Article Text

Download PDFPDF

1711 The Relationship between the First Episode of Wheezing and Matrix Metalloproteinases-9 and –2 and Timp-1 Levels in Preterm Infants
  1. RG Sezer1,
  2. A Bozaykut1,
  3. IA Tanju2,
  4. G Aydemir2,
  5. LP Seren1,
  6. S Hira3,
  7. O Ozcan3
  1. 1Department of Pediatrics, Zeynep Kamil Maternity and Childrens’ Disease Training and Research State Hospital
  2. 2Department of Pediatrics
  3. 3Department of Biochemistry, GATA Teaching Hospital, Istanbul, Turkey


Background Elevated concentrations of matrix metalloproteinases (MMP) have been associated with neonatal morbidity. There are no data on the serum levels of MMP-2, MMP-9, tissue inhibitors of matrix metalloproteinase (TIMP-1) from preterm infants recovering from these morbidities. We aimed to compare MMP-2, MMP-9, and TIMP-1 levels in preterm and term infants hospitalized with their first episode of wheezing.

Methods We prospectively evaluated 18 preterm infants with a history of chronic lung disease, respiratory distress syndrome and 14 age- and sex- matched term infants who were admitted for a first episode of wheezing. We quantified total serum concentrations of MMP-2, MMP-9, and TIMP-1 to assess whether these serum markers levels were associated with wheezing with a history of oxygen therapy during the neonatal period.

Results Upon hospitalization for the first episode of wheezing, MMP-2 and TIMP-1 levels were higher in preterm infants than in term infants.

[Comparison of MMP-2, MMP-9, and TIMP-1 levels]

In contrast, there was no significant relationship between MMP-9 levels or the MMP-9/TIMP-1 ratio between preterm and term infants (univariate analysis). The area under the ROC curve for MMP-2 was 0.70 (95% CI 0.51–0.89, p=0.04). The area under the curve for TIMP-1 was 0.78 (95% CI 0.61–0.94, p=0.007). MMP-9, MMP-2, and TIMP-1 levels did not correlate with gestational age, gender, severity of wheezing.

Conclusion Elevated serum MMP-2 and TIMP-1 levels appear to increase the risk for wheezing. Further studies will be required to determine whether therapeutic inhibitors will prevent recurrent lung morbidities in preterm infants.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.